) ( 1 (51) International Patent Classification: (71) Applicant: OBSIDIAN THERAPEUTICS, INC. C12N 9/88 (2006.01) A61K 39/00 (2006.01) [US/US]; 1030 Massachusetts Avenue, Suite 400, Cam- C07K 14/705 (2006.01) bridge, MA 02138 (US). (21) International Application Number: (72) Inventors: SURI, Vipin; 3 Coolidge Road, Belmont, MA PCT/US2020/021596 02478 (US). RICHARDSON, Celeste; 199 Wolcott Road, Brookline, MA 02467 (US). DOLINSKI, Brian; c/o Ob¬ (22) International Filing Date: sidian Therapeutics, Inc., 1030 Massachusetts Avenue, 06 March 2020 (06.03.2020) Suite 400, Cambridge, MA 02138 (US). KULKARNI, Ab- (25) Filing Language: English hishek; 360 Tappan Street #3, Brookline, MA 02445 (US). INNISS, Mara Christine; 11 Highland Ave., Unit 2, Bev¬ (26) Publication Language: English erly, MA 01915 (US). SUN, Dexue; c/o Obsidian Thera¬ (30) Priority Data: peutics, Inc., 1030 Massachusetts Avenue, Suite 400, Cam¬ 62/815,399 08 March 2019 (08.03.2019) US bridge, MA 02138 (US). WEISMAN, Elizabeth Jane; c/ 62/815,402 08 March 2019 (08.03.2019) US o Obsidian Therapeutics, Inc., 1030 Massachusetts Avenue, 62/826,487 29 March 2019 (29.03.2019) US Suite 400, Cambridge, MA 02138 (US). OLINGER, Grace 62/826,443 29 March 2019 (29.03.2019) US Y.; 22 Water Street, #43 1, Cambridge, MA 02141 (US). 62/835,552 18 April 2019 (18.04.2019) US HELLER, Scott Francis; 559 Plain St., Stoughton, MA 62/835,548 18 April 2019 (18.04.2019) US 02072 (US). GORI, Jennifer Leah; 20 Spalding Street, 62/860,388 12 June 2019 (12.06.2019) US Unit 1, Jamaica Plain, MA 02130 (US). OLS, Michelle Lynn; 65 Oak Avenue, Northborough, MA 01532 (US). ELPEK, Kutlu Goksu; c/o Obsidian Therapeutics, Inc., (54) Title: HUMAN CARBONIC ANHYDRASE 2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION FIGURE 1 Ligand concentration (µΜ) (57) Abstract: The present disclosure provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities. In particular, the present application is directed to fusion proteins comprising a fragment of human human carbonic anhydrase 2 and a chimeric antigen receptor (CAR). The activity of the destabilizing domain can be regulated by externally administered agents. [Continued on nextpage] 1030 Massachusets Avenue, Suite 400, Cambridge, MA 02138 (US). EZELL, Tucker; c/o Obsidian Therapeutics, Inc., 1030 Massachusetts Avenue, Suite 400, Cambridge, MA 02138 (US). SCHEBESTA, Michael; c/o Obsidian Therapeutics, Inc., 1030 Massachusetts Avenue, Suite 400, Cambridge, MA 02138 (US). FLEURY, Michelle Lois; 63 Dana Street, Apartment 7, Cambridge, MA 02138 (US). SETHI, Dhruv Kam; 8 1 Burgess Avenue, Westwood, MA 02090 (US). (74) Agent: ALBERDI, Fernando; HonigmanLLP, 650 Trade Centre Way, Suite 200, Kalamazoo, MI 49002-0402 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available) : ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) HUMAN CARBONIC ANHYDRASE 2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims benefit of priority to U.S. Provisional Application No. 62/815,399, filed March 8, 2019; U.S. Provisional Application No. 62/815,402, filed March 8, 2019; U.S. Provisional Application No. 62/826,487, filed March 29, 2019; U.S. Provisional Application No. 62/826,443 filed March 29, 2019; U.S. Provisional Application No. 62/835,548 filed April 18, 2019; U.S. Provisional Application No. 62/835,552, filed April 18, 2019; and U.S. Provisional Application No. 62/860,388, filed June 12, 2019. The entire contents of the aforementioned applications are incorporated herein by reference in their entireties. REFERENCE TO THE SEQUENCE LISTING [0002] The instant application contains a "lengthy" Sequence Listing which has been submitted via CD-R in lieu of a printed paper copy and is hereby incorporated by reference in its entirety. Said CD-R, created and recorded on March 6, 2020, are labeled "CRF", "Copy 1", "Copy 2" "Copy 3," and “Copy 4” respectively, and each contains only one identical 699,270,904 bytes (measured in MS-WINDOWS) file named 268052-462540_SL.txt. The machine-readable format of each CD-R is IBM-PC and the operating system of each compact disc is MS-Windows. FIELD [0003] The present disclosure relates to destabilizing domains (DDs) derived from human carbonic anhydrase 2 (CA2) which can tune protein stability for at least one payload, and compositions and methods of use thereof. Provided in the present disclosure include polypeptides of CA2 biocircuit systems, CA2 effector modules, stimulus response elements (SREs), polynucleotides encoding the same, vectors and cells containing the polypeptides and/or polynucleotides for use in cancer immunotherapy. BACKGROUND [0004] Gene and cell therapies are revolutionizing medicine and offering new promise for the treatment of previously intractable conditions. However, most current technologies do not allow titration of the timing or levels of target protein induction. This has rendered many potential gene and cell therapy applications difficult or impossible to safely and effectively deploy. [0005] Inadequate exogenous and/or endogenous gene control is a critical issue in many gene and cell therapy settings. This lack of tunability also makes it difficult to safely express proteins with narrow or uncertain therapeutic windows or those requiring more titrated or transient expression. [0006] One approach to regulated protein expression or function is the use of Destabilizing Domains (DDs). Destabilizing domains are small protein domains that can be appended to a target protein of interest. DDs render the attached protein of interest unstable in the absence of a DD-binding ligand and the protein of interest is rapidly degraded by the ubiquitin-proteasome system of the cell. However, when a specific small molecule DD-binding ligand binds to the DD, the attached protein of interest is stabilized, and protein function is achieved. [0007] DD technology forms the basis of a new class of cell and gene therapies that can deliver tunable and temporal control of gene expression and function, expanding the universe of protein therapeutics that can be safely and effectively incorporated into cell and gene therapy modalities. SUMMARY [0008] The present disclosure provides novel protein domains derived from human carbonic anhydrase 2 (CA2) displaying small molecule dependent stability. Such protein domains are called destabilizing domains (DDs). In the absence of its binding ligand, the DD is destabilizing and causes degradation of a payload fused to the DD (e.g., a protein of interest (POI), while in the presence of its binding ligand, the fused DD and payload can be stabilized, and its stability is dose dependent. [0009] In a first aspect, the present disclosure provides a composition comprising an effector module. The effector module comprises a stimulus response element (SRE) and at least one payload which is operably linked to the SRE. In various embodiments, the SRE comprises a destabilizing domain (DD), wherein the DD comprises a region of or the whole human carbonic anhydrase 2 (CA2; SEQ ID NO. 11717), and further comprises a H122Y mutation in the amino acid at position 122 (H122) of SEQ ID NO. 11717. [0010] In a second aspect, the present disclosure provides a composition comprising an effector module. The effector module comprises a stimulus response element (SRE) and at least one payload which is operably linked to the SRE. In various embodiments, the SRE comprises a destabilizing domain (DD), wherein the DD comprises a region of or the whole human carbonic anhydrase 2 (CA2; SEQ ID NO. 11717), and further comprises a E106D mutation in the amino acid at position 106 (E106) of SEQ ID NO. 11717. [0011] In a third aspect of the present disclosure, a composition comprising an effector module is provided. The effector module comprises a stimulus response element (SRE) and at least one payload which is operably linked to the SRE. In various embodiments, the SRE comprises a destabilizing domain (DD), wherein the DD comprises a region of or the whole human carbonic anhydrase 2 (CA2; SEQ ID NO. 11717), and further comprises a W208S mutation in the amino acid at position 208 (W208) of SEQ ID NO. 11717. [0012] In a fourth aspect of the present disclosure, a composition comprising an effector module is provided.